# US 2018/0021257 A1 · Water-soluble pharmaceutical composition comprising at least one therapeutically active substance and at least one substance capable of forming micelles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021257 A1
- Document ID: US20180021257A1
- Status: Published application
- Kind: A1
- Application number: 15/547,300
- Filed: 2016-01-28
- Published: 2018-01-25
- Earliest claimed: 2015-01-30
- Assignees: Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet); Centro De Excelencia En Productos Y Procesos Cordoba
- Applicants: Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet); Centro De Excelencia En Productos Y Procesos Cordoba
- Inventors: Dante Miguel BELTRAMO; Roxana Valeria ALASINO; Nestor GARCIA
- Web page: https://patentgrep.com/patent/US20180021257A1

## CPC

- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A water-soluble pharmaceutical composition comprises at least one therapeutically active substance and at least one substance capable of forming micelles, wherein the therapeutically active substance is selected from drugs having hydrophobic properties for treating cancer patients, and the at least one substance capable of forming micelles is selected from antibiotics of the lipoglycopeptide type, such as teicoplanin, dalbavancin and oritavancin.

## Claims

### Claim 1

A water-soluble pharmaceutical composition comprising at least a therapeutically active substance and at least a substance capable of forming micelles, wherein such therapeutically active substance is selected from drugs with hydrophobic characteristics for the treatment of cancer patients and wherein such substance capable of forming micelles is selected from Teicoplanin, Dalbavancin and Oritavancin compounds.

### Claim 2 (depends on 1)

A water-soluble pharmaceutical composition according to claim 1, wherein such drugs with hydrophobic characteristics for treating cancer patients are selected from antitumor drugs.

### Claim 3 (depends on 2)

A water-soluble pharmaceutical composition according to claim 2, further comprising at least an antitumor drug with hydrophobic characteristics and at least a substance capable of forming micelles selected from Teicoplanin, Dalbavancin and Oritavancin compounds, wherein such compounds are forming micelles and wherein such antitumor drug with hydrophobic characteristics is attached to the micelles non-covalently.

### Claim 4 (depends on 2)

A water-soluble pharmaceutical composition according to claim 2, further comprising an antitumor drug with hydrophobic characteristics and a substance capable of forming micelles, wherein such antitumor drug is Paclitaxel and wherein such substance capable of forming micelles is Teicoplanin.

### Claim 5 (depends on 4)

A water-soluble pharmaceutical composition according to claim 4, further comprising Paclitaxel and Teicoplanin according to a molar ratio ranging from 1:5 to 1:100.

### Claim 6 (depends on 5)

A water-soluble pharmaceutical composition according to claim 5, further comprising between about 1 mg/ml and 10 mg/ml of Paclitaxel and 10 mg/ml and 200 mg/ml of Teicoplanin.

### Claim 7 (depends on 2)

A water-soluble pharmaceutical composition according to claim 2, further comprising an antitumor drug with hydrophobic characteristics and a substance capable of forming micelles, wherein such antitumor drug is Docetaxel and wherein such substance capable of forming micelles is Teicoplanin.

### Claim 8 (depends on 7)

A water-soluble pharmaceutical composition according to claim 7, further comprising Docetaxel and Teicoplanin according to a molar ratio ranging from about 1:5 to 1:100.

### Claim 9 (depends on 8)

A water-soluble pharmaceutical composition according to claim 8, further comprising between about 1 mg/ml and 10 mg/ml of Docetaxel and 10 mg/ml and 200 mg/ml of Teicoplanin.

### Claim 10 (depends on 1)

A water-soluble pharmaceutical composition according to claim 1, wherein the composition is a sterile injectable composition.

### Claim 11 (depends on 1)

A water-soluble pharmaceutical composition according to claim 1, wherein the composition is a lyophilized composition.

### Claim 12 (depends on 11)

A water-soluble pharmaceutical composition according to claim 11, wherein such lyophilized composition can be reconstituted with a solvent selected from a solution of distilled water, a saline solution (NaCl 0.9%) a phosphate saline buffer solution (PBS), distilled water containing 5% of dextrose, a saline solution with 5% dextrose and human albumin solution by 20%, to obtain a sterile translucent composition.

### Claim 13 (depends on 1)

A water-soluble pharmaceutical composition according to claim 1, wherein the composition is a liquid composition.

### Claim 14 (depends on 1)

A water-soluble pharmaceutical composition according to claim 1, further comprising micelles of at least one selected compound such as Teicoplanin, wherein such micelles are loaded with antitumor drugs with hydrophobic characteristics and wherein such micelles are non-covalently coated with albumin.

### Claim 15 (depends on 14)

A water-soluble pharmaceutical composition according to claim 14, wherein albumin is selected from human albumin, recombinant human albumin, human albumin containing fatty acids and bovine albumin.

### Claim 16 (depends on 15)

A water-soluble pharmaceutical composition according to claim 15, wherein the antibiotic:albumin ratio ranges from about 1:2 to 1:4 (w/w).

### Claim 17 (depends on 15)

A water-soluble pharmaceutical composition according to claim 15, wherein albumin comprises folic acid covalently coupled.

### Claim 18 (depends on 17)

A water-soluble pharmaceutical composition according to claim 17, wherein the amount of folic acid covalently attached to albumin ranges from about 1 to 20% of total albumin.

### Claim 19 (depends on 1)

A water-soluble, lyophilized and sterile pharmaceutical composition according to claim 1, wherein once re-suspended in a solvent selected from a solution of distilled water, a saline solution (NaCl 0.9%) a phosphate buffer solution (PBS), distilled water containing 5% of dextrose, saline solution with 5% dextrose and human albumin solution by 20% allows obtaining a final concentration ranging from 0.1 to 10 mg/ml of an antitumor drug selected from Paclitaxel and Docetaxel.

### Claim 20 (depends on 19)

A water-soluble, lyophilized and sterile pharmaceutical composition according to claim 19, wherein once re-suspended in a solvent selected from a solution of distilled water, a saline solution (NaCl 0.9%), phosphate buffer solution (PBS), distilled water containing 5% of dextrose, saline solution with 5% of dextrose and human albumin solution by 20% allows obtaining a final concentration ranging from 1 to 10 mg/ml of an antitumor drug selected from Paclitaxel and Docetaxel.

### Claim 21 (depends on 20)

A water-soluble, lyophilized and sterile pharmaceutical composition according to claim 20, wherein once re-suspended in a solvent selected from a solution of distilled water, a saline solution (NaCl 0.9%), phosphate buffer solution (PBS), distilled water containing 5% of dextrose, saline solution with 5% of dextrose and human albumin solution by 20% allows obtaining a final concentration ranging from 5 to 10 mg/ml of an antitumor drug selected from Paclitaxel and Docetaxel.

### Claim 22 (depends on 11)

A water-soluble, lyophilized and sterile pharmaceutical composition according to claim 11, wherein once dissolved, it has pH ranging between 6 and 8.

### Claim 23 (depends on 22)

A water-soluble, lyophilized and sterile pharmaceutical composition according to claim 22, wherein once dissolved, it has a pH ranging between 6 and 7.5.

### Claim 24 (depends on 1)

A water-soluble, lyophilized and sterile pharmaceutical composition according to claim 1 having an average size lower than 200 nm.

### Claim 25 (depends on 24)

A water-soluble, lyophilized and sterile pharmaceutical composition according to claim 24 having an average size ranging between 5 nm and 80 nm.

### Claim 26 (depends on 25)

A water-soluble, lyophilized and sterile pharmaceutical composition according to claim 25 having an average size ranging between about 5 nm and about 25 nm.

### Claim 27

A water-soluble pharmaceutical composition comprising at least a therapeutically active substance and at least a substance capable of forming micelles, wherein such therapeutically active substance is selected from antifungal drugs with hydrophobic characteristics and wherein such substance capable of forming micelles is selected from Teicoplanin, Dalbavancin and Oritavancin compounds.

### Claim 28 (depends on 27)

A water-soluble pharmaceutical composition according to claim 27, wherein such therapeutically active substance selected from antifungal drugs is Amphotericin B and such substance capable of forming micelles is Teicoplanin.
